Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1986 1
2008 1
2010 2
2011 1
2012 2
2013 3
2014 4
2017 1
2020 1
2021 5
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Drew Y, et al. Among authors: roxburgh p. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249. Clin Cancer Res. 2024. PMID: 37939124 Free PMC article. Clinical Trial.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV; Scottish Genomes Partnership; Cooke SL, Ratnayake G, McNally O, Traficante N; Australian Ovarian Cancer Study12,13; DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Ho GY, et al. Among authors: roxburgh p. Cancer Res. 2022 Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. Cancer Res. 2022. PMID: 36206301 Free PMC article.
Squamous carcinoma of the ovary.
Roxburgh P, Glasspool R. Roxburgh P, et al. Curr Oncol Rep. 2014 Dec;16(12):413. doi: 10.1007/s11912-014-0413-1. Curr Oncol Rep. 2014. PMID: 25344339 Review.
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R. Spiliopoulou P, et al. Among authors: roxburgh p. Int J Gynecol Cancer. 2021 Jul;31(7):1037-1044. doi: 10.1136/ijgc-2021-002467. Epub 2021 May 20. Int J Gynecol Cancer. 2021. PMID: 34016703
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIG) symptom benefit committee. Kurtz JE, et al. Among authors: roxburgh p. Gynecol Oncol. 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. Gynecol Oncol. 2021. PMID: 33612336 Review.
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, Cheng Z, Ennis DP, Iyer N, McNamara S, Natoli M, Mason S, Blyth K, Adams PD, Roxburgh P, Fuchter MJ, Brown B, McNeish IA. Spiliopoulou P, et al. Among authors: roxburgh p. Mol Cancer Ther. 2022 Apr 1;21(4):522-534. doi: 10.1158/1535-7163.MCT-21-0743. Mol Cancer Ther. 2022. PMID: 35131874 Free PMC article.
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, Croy I, McCluggage WG, Williams ARW, Bartos C, Iida Y, Okamoto A, Dougherty B, Barrett JC, March R, Matakidou A, Roxburgh P, Semple CA, Harkin DP, Kennedy R, Herrington CS, Gourley C. Hollis RL, et al. Among authors: roxburgh p. Clin Cancer Res. 2022 Aug 15;28(16):3546-3556. doi: 10.1158/1078-0432.CCR-22-0368. Clin Cancer Res. 2022. PMID: 35696721 Free PMC article.
CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
Wohlmuth C, Djedovic V, Kjaer SK, Jensen A, Glasspool R, Roxburgh P, DeFazio A, Johnatty SE, Webb PM, Modugno F, Lambrechts D, Schildkraut JM, Berchuck A, Thomsen LCV, Bjorge L, Høgdall E, Høgdall CK, Goode EL, Winham SJ, Matsuo K, Karlan BY, Lester J, Goodman MT, Thompson PJ, Pejovic T, Riggan MJ, Lajkosz K, Tone A, May T. Wohlmuth C, et al. Among authors: roxburgh p. Cancers (Basel). 2022 Apr 13;14(8):1954. doi: 10.3390/cancers14081954. Cancers (Basel). 2022. PMID: 35454861 Free PMC article.
30 results